Nevertheless, these findings document for the first time that high level expression of Bcl-B is usually a common feature of several types of human malignancy. The functional significance of Bcl-B expression in AZD6482 epithelial malignancies remains to be determined. as well as in non C small cell lung cancers (= 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast malignancy (= 0.009), microsatellite stability (= 0.0002), and left-sided anatomic location (= 0.02) of colorectal cancers, as well as with greater incidence of death from prostate malignancy (= 0.005) and shorter survival of patients with small cell lung cancer AZD6482 (= 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better end result (= 0.01) and more differentiated tumor histology ( 0.0001). Conclusions Tumor-specific alterations in Bcl-B expressionmay define subsets of nonepithelial and epithelial neoplasms with unique clinical behaviors. Defective apoptosis represents one of the six acknowledged cardinal features of malignancy (1). Bcl-2 family proteins are evolutionarily conserved regulators of cell PITPNM1 life and death. In humans, six antiapoptotic users of the Bcl-2 family have been recognized, including Bcl-2, Bcl-XL, Mcl-1, Bcl-W, Bfl-1, and Bcl-B (2). Overexpression of Bcl-2 and some other antiapoptotic members of the Bcl-2 family has been documented in human cancers (examined in ref. 3). Given that investigational therapies targeting specific Bcl-2 family proteins or their encoding mRNAs are now in clinical trials, it is important to define which Bcl-2 family proteins are overexpressed in various types of malignancy, so that appropriate targeted therapies can be matched to specific malignancies. Bcl-B (also known as Bcl2-L-10) was the last antiapoptotic member of the human Bcl-2 family to be recognized (4, 5), and relatively little is known about its functions. Bcl-B contains conserved BH1, BH2, BH3-like, and BH4 domains, as well as a COOH terminal transmembrane domain name, common of antiapoptotic Bcl-2 family proteins that target intracellular membranes of mitochondria (4, 5). Dimerization of proapoptotic and antiapoptotic Bcl-2 family proteins plays an important role in controlling their activity (6, 7). The Bcl-B protein was shown to differentially bind proapoptotic Bcl-2 family members (4). Thus, Bcl-B may have a unique pattern of selectivity for binding AZD6482 to numerous proapoptotic members of the Bcl-2 family, suggesting a specific role for this protein in controlling cell life and death. Although in the beginning acknowledged for its antiapoptotic activity, the mouse orthologue of Bcl-B reportedly displays either antiapoptotic or proapoptotic activity, depending on cellular context (8, 9). In this regard, we recently reported that Bcl-B binds orphan nuclear receptor Nur77/TR3, which converts the phenotype of Bcl-B from antiapoptotic to proapoptotic (10). Thus, Bcl-B is similar to Bcl-2 in its ability to display opposing effects on apoptosis based on protein interactions and other factors (11). Heretofore, analysis of Bcl-B protein expression in human tissues or cancers has not been explained. A variety of publicly available DNA microarray datasets have suggested Bcl-B mRNA is AZD6482 usually widely expressed in human tissues and many cancers but have drawn little attention and permitted few conclusions. The closest orthologue of Bcl-B in mice is usually Boo/Diva, with 49% amino acid identity. However, Boo/Diva expression in mice seems to be limited to ovary and testis (8, 9), suggesting that this murine gene is usually regulated differently than its closest human counterpart and highlights an important species-specific difference. By generating monospecific AZD6482 antibodies that identify Bcl-B, we have investigated Bcl-B protein expression in normal human tissues and in several types of human malignancy by immunohistochemistry, correlating the expression results with clinically relevant variables. Materials and Methods Patient specimens Informed consent was obtained in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Boards of each institution that participated. Bone marrow biopsies from 165 patients, 114 with symptomatic multiple myeloma (MM), 19 with indolent MM, 13 with monoclonal gammopathy of undetermined significance (MGUS), and 19 with reactive plasmacytosis, were obtained from Veterans Affairs Medical Center (VA Hospital) of Los Angeles. Patients were categorized according to WHO criteria, assessing the plasma count in bone marrow (group 1, 0-10%; group 2, 11-30%; group 3, 30%; ref. 12). Tissue microarrays (TMA) comprising paraffin-embedded lymph node specimens from 48 patients diagnosed with diffuse large B-cell lymphomas (DLBCL) and from 57 patients with follicular lymphoma were provided by the Robert H. Lurie Comprehensive Cancer Center, Northwestern University or college. Tumor specimens were obtained from 79 small cell lung malignancy (SCLC) patients with limited disease who were treated by surgery followed by chemotherapy using numerous multidrug regimens at the Thoracic Surgery.